Bezlotoxumab is a fully human monoclonal antibody that binds specifically to Clostridium difficile toxin B. By neutralizing the toxin, Bezlotoxumab prevents epithelial damage and colitis, thereby reducing the recurrence of C. difficile infections and protecting intestinal integrity.